Immatics NV Ordinary Shares IMTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMTX is a good fit for your portfolio.
News
-
Immatics Announces Full Year 2023 Financial Results and Corporate Update
-
Immatics shares rise on Moderna cancer collaboration
-
Immatics Shares Rise Premarket on Collaboration With Moderna
-
Immatics shares jump after investment from Bristol Myers Squibb
-
Bristol Myers Squibb Invests $35 Million in Immatics
Trading Information
- Previous Close Price
- $10.01
- Day Range
- $9.95–10.26
- 52-Week Range
- $6.46–13.16
- Bid/Ask
- $9.95 / $10.65
- Market Cap
- $1.03 Bil
- Volume/Avg
- 249,982 / 431,797
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.48
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 343
- Website
- https://www.immatics.com
Comparables
Valuation
|
Metric
|
IMTX
|
MRUS
|
VVY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.33 | 7.29 | 0.56 |
Price/Sales | 13.48 | 52.76 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
IMTX
MRUS
VVY
Financial Strength
|
Metric
|
IMTX
|
MRUS
|
VVY
|
|---|---|---|---|
Quick Ratio | 2.76 | 5.19 | 18.38 |
Current Ratio | 2.87 | 5.34 | 19.45 |
Interest Coverage | −132.38 | — | −104.42 |
Quick Ratio
IMTX
MRUS
VVY
Profitability
|
Metric
|
IMTX
|
MRUS
|
VVY
|
|---|---|---|---|
Return on Assets (Normalized) | −15.61% | −30.87% | −61.97% |
Return on Equity (Normalized) | −30.30% | −42.51% | −72.07% |
Return on Invested Capital (Normalized) | −33.80% | −44.25% | −68.80% |
Return on Assets
IMTX
MRUS
VVY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nqvbdfbvqm | Zjjqd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Klpfgmr | Rprqmtt | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nfvjyss | Pptyjyw | $97.8 Bil | |
MRNA
| Moderna Inc | Zmdpkfgqv | Xwxg | $41.3 Bil | |
ARGX
| argenx SE ADR | Gfdnclltw | Rtf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Znbhcclh | Npcyl | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sffdvkn | Glyswxy | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zcwrhbbb | Vqwnbh | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gtmympsyl | Vzlvkb | $12.5 Bil | |
INCY
| Incyte Corp | Fnhjqzcj | Skttjps | $11.6 Bil |